Ping Lu

机构：Naval University of Engineering, Shanxi Provincial Cancer Hospital, First Affiliated Hospital of Xinxiang Medical University, Henan Medical University · ORCID：0000-0001-5359-949X

发表论文 24 篇 · 总被引 264 次 · h-index 7

代表论文

• Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial (2023 · Journal of Thoracic Oncology · 被引 72)
• Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report (2022 · Cell Transplantation · 被引 58)
• Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study (2024 · Journal for ImmunoTherapy of Cancer · 被引 26)
• Protein post-translational modifications and tumor immunity: A pan-cancer perspective (2025 · Physics of Life Reviews · 被引 25)
• ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC). (2024 · Journal of Clinical Oncology · 被引 24)
• Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study (2024 · European Journal of Cancer · 被引 21)